Estrogen receptor β target gene expression reveals novel repressive functions in aggressive breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Inflammatory breast cancer (IBC) is an aggressive, highly metastatic breast cancer subtype.
• IBC is often estrogen receptor alpha (ERα)-negative, limiting treatment options.
• Estrogen receptor beta (ERβ) has shown potential in reducing IBC metastasis, linked to inhibited cell migration.

Purpose of the Study:

• To comprehensively identify the molecular signaling pathways driven by ERβ that mediate its anti-metastatic effects in IBC.
• To uncover direct ERβ target genes and regulatory mechanisms using a genomics approach.
• To explore the clinical relevance of ERβ downstream targets in patient outcomes.

Main Methods:

• Genomics approach including mRNA and miRNA profiling.
• Chromatin immunoprecipitation sequencing (ChIP-seq) to identify ERβ binding sites.
• Analysis of ERβ-activated IBC cells (transfected and endogenous).
• Cross-examination of genomic data to identify regulatory motifs and direct targets.
• Clinical dataset analysis to correlate downstream factors with patient survival.

Main Results:

• Identified key regulatory binding motifs and direct mRNA and miRNA targets of ERβ in IBC cells.
• Uncovered ERβ-mediated regulation of pathways involved in cellular development, metabolism, and the tumor microenvironment.
• Demonstrated association of ERβ downstream factors with patient outcomes in clinical datasets.

Conclusions:

• ERβ signaling exerts anti-metastatic effects in IBC through complex molecular pathways.
• Specific downstream targets of ERβ represent potential therapeutic candidates for IBC treatment.
• ERβ plays a tumor-repressive role in breast cancer, offering a novel therapeutic strategy.